We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ResMed (RMD - Free Report) recently expanded its AirFit mask portfolio with the introduction of its first minimal-contact full face CPAP mask — AirFit F30. The company plans to launch the product in selected geographies in late-2018.
AirFit F30 in Detail
FeaturingResMed’s latest QuietAir vent, AirFit F30 helps users sleep comfortably, decrease facial marks and wear glasses in bed. Moreover, the mask is easy to put on and take off as it comes with magnetic clips. Per a ResMed study, AirFit F30 could fit 93% of users well in spite of having just two cushion sizes and one headgear.
Per the company, the AirFit F30 will also permit faster setups and simpler inventory management for home medical equipment providers.
Market Potential
Globally, over 100 million are estimated to be suffering from sleep apnea (per an article published on The Sleep Zone). The increasing incidence has driven demand for sleep apnea devices. Per a report by MarketsandMarkets, the global sleep apnea devices market is expected to see a CAGR of 7.8% to reach $6.49 billion between 2018 and 2023.
Going by the same report, North America is projected to be the largest market for sleep apnea devices in 2018.
Rising healthcare expenditures, increasing obesity, unhealthy lifestyle practices along with expanded treatment options are expected to continue driving demand for sleep apnea devices. In view of the data, we believe the latest development will help ResMed cash in on opportunities in this niche market.
Strong Emphasis on Product Development
In order to maintain its leadership position in the SDB market and to expand its sales base, ResMed is focusing on product development and innovation. In this regard, ResMed is encouraged with the positive feedback pertaining to the QuietAir technology, which is part of the AirFit F20 full face mask.
Loaded with innovation to improve mask fit, comfort and ease of use, the new-generation ResMed masks are the result of more than three years of research and development. In addition, the company is seeking new applications for significant unmet medical needs.
Further, ResMed continues to see strong adoption of AirFit F20 full face mask and AirFit N20 nasal mask products globally. The company also seems to be upbeat about the success of its N20 Classic, which is designed particularly for countries in Europe.
Share Price Performance
Over the past year, shares of ResMed have outperformed its industry. Per the latest price movement, the stock has gained 41.8% compared with the industry’s rise of 19.9%.
Amedisys’ long-term expected earnings growth rate is 18.6%. The stock holds a Zacks Rank #1 at the moment.
Masimo’s long-term expected earnings growth rate is 14.8%. The stock has a Zacks Rank #2 (Buy) at present.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025.
Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Image: Bigstock
ResMed Unveils AirFit F30, Expands AirFit Mask Portfolio
ResMed (RMD - Free Report) recently expanded its AirFit mask portfolio with the introduction of its first minimal-contact full face CPAP mask — AirFit F30. The company plans to launch the product in selected geographies in late-2018.
AirFit F30 in Detail
FeaturingResMed’s latest QuietAir vent, AirFit F30 helps users sleep comfortably, decrease facial marks and wear glasses in bed. Moreover, the mask is easy to put on and take off as it comes with magnetic clips. Per a ResMed study, AirFit F30 could fit 93% of users well in spite of having just two cushion sizes and one headgear.
Per the company, the AirFit F30 will also permit faster setups and simpler inventory management for home medical equipment providers.
Market Potential
Globally, over 100 million are estimated to be suffering from sleep apnea (per an article published on The Sleep Zone). The increasing incidence has driven demand for sleep apnea devices. Per a report by MarketsandMarkets, the global sleep apnea devices market is expected to see a CAGR of 7.8% to reach $6.49 billion between 2018 and 2023.
Going by the same report, North America is projected to be the largest market for sleep apnea devices in 2018.
Rising healthcare expenditures, increasing obesity, unhealthy lifestyle practices along with expanded treatment options are expected to continue driving demand for sleep apnea devices. In view of the data, we believe the latest development will help ResMed cash in on opportunities in this niche market.
Strong Emphasis on Product Development
In order to maintain its leadership position in the SDB market and to expand its sales base, ResMed is focusing on product development and innovation. In this regard, ResMed is encouraged with the positive feedback pertaining to the QuietAir technology, which is part of the AirFit F20 full face mask.
Loaded with innovation to improve mask fit, comfort and ease of use, the new-generation ResMed masks are the result of more than three years of research and development. In addition, the company is seeking new applications for significant unmet medical needs.
Further, ResMed continues to see strong adoption of AirFit F20 full face mask and AirFit N20 nasal mask products globally. The company also seems to be upbeat about the success of its N20 Classic, which is designed particularly for countries in Europe.
Share Price Performance
Over the past year, shares of ResMed have outperformed its industry. Per the latest price movement, the stock has gained 41.8% compared with the industry’s rise of 19.9%.
Zacks Rank and Key Picks
ResMed carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Intuitive Surgical (ISRG - Free Report) , Amedisys, Inc. (AMED - Free Report) and Masimo Corp. (MASI - Free Report) .
Intuitive Surgical’s long-term expected earnings growth rate is 14.7%. The stock currently carries a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Amedisys’ long-term expected earnings growth rate is 18.6%. The stock holds a Zacks Rank #1 at the moment.
Masimo’s long-term expected earnings growth rate is 14.8%. The stock has a Zacks Rank #2 (Buy) at present.
5 Companies Verge on Apple-Like Run
Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2018 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025.
Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs. A bonus Zacks Special Report names this breakthrough and the 5 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains.
Click to see them right now >>